Prof. Jing Wang 王静
Chief Physician, Professor
Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Immunotherapy, targeted therapy, surgery, and chemoradiotherapy for ovarian, cervical, and endometrial cancers. Participation in clinical trials for new anticancer drugs.
Dr. Wang holds a medical doctorate and serves as Professor, Chief Physician, and Director of the Early Clinical Research Center at Hunan Cancer Hospital. A recipient of the State Council Special Allowance, Dr. Wang leads a team supported by national and provincial grants. Research findings have been presented at international conferences including SGO, IGCS, ASCO, ESMO, and ASCCP.
Professional roles
- Vice Chair, Gynecologic Oncology Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Gynecologic Oncology Professional Committee, China Maternal and Child Health Association
- Vice Chair, Ovarian Cancer Quality Control Expert Committee, National Cancer Center
- Editor-in-Chief, Tumor Pharmacy
Name order: in Chinese the family name comes first (Wang Jing). Papers usually list the name as Jing Wang or Wang J.
Selected publications
120 papers on PubMed matched by name and affiliation; 35 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Nutr Biochem, 2026 (senior author): Vitamin E and related tocols in cancer: Unraveling the paradox of antioxidant and pro-oxidant roles. PubMed 41534603
- Genes Dis, 2026 (senior author): Platinum-resistant ovarian cancer: From mechanisms to treatment strategies. PubMed 41376855
- Commun Biol, 2025 (senior author): HKDC1 promotes ovarian cancer progression through boosting lipid metabolism and immune escape by stabilizing G6PC/G6PC2. PubMed 40234623
- Front Pharmacol, 2025 (senior author): Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II. PubMed 39995412
- J Exp Clin Cancer Res, 2024 (senior author): Correction: TRPM7 promotes the epithelial- mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling. PubMed 39434150
- Immunology, 2024 (senior author): Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. PubMed 38618976
- Clin Cancer Res, 2024 (senior author): Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. PubMed 38372727
- Biochem Pharmacol, 2023 (senior author): Roles of TRPM7 in ovarian cancer. PubMed 37839677
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion